Alnylam Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALNY research report →
Range $225 – $455
Price Chart
About the company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders.
- CEO
- Yvonne L. Greenstreet
- IPO
- 2004
- Employees
- 2,500
- HQ
- Cambridge, MA, US
AI snapshot
Six angles, distilled from the data.
The stock is in a deep reset after a major year-long drawdown, but it has stabilized well above the 52-week low. Price remains far below the 200-day average, so the regime is still corrective rather than trending higher. The setup favors a base-building phase unless it can reclaim longer-term moving averages.
Street sentiment stays constructive, with a Buy consensus and a $326.73 median target versus a $149.91 share price. Recent changes have turned more cautious, including a downgrade to Neutral and several target cuts, but the broader rating mix still leans bullish with 37 Buys against 14 Holds and 1 Sell.
The earnings trend is mixed but capable of sharp upside surprises, with 6 beats in the last 8 quarters and a 976.7% EPS beat in the latest report. Next-year EPS estimates sit below the current TTM figure, so shareholders should watch whether pipeline execution and margin durability can keep results ahead of expectations.
Recent insider activity leans to net selling, but much of the flow is automatic or non-discretionary. The clearest signal is modest open-market buying from two directors, offset by sales from an EVP and repeated director sales, while gifts, awards, and exempt exercises dilute the read.
Profitability is strong for a biotech platform, with a 77.3% gross margin and a 52.85% net margin. Growth remains solid at 16.7% revenue growth year over year, while free cash flow of $582.8 million and net cash of $1.63 billion give the balance sheet room to fund the pipeline.
ALNY screens as a premium biotech with a 7.57 P/E and a valuation that still sits below the average target, though the market has clearly de-rated the name. Versus peers, the appeal is profitability and cash generation; the risk is that the stock must prove its pipeline can justify the long-term target stack.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $19.26B
- P/E
- 7.68
- Fwd P/E
- 7.81
- PEG
- 0.00
- P/S
- 4.18
- P/B
- 5.81
- EV/EBITDA
- 16.40
- Div Yield
- 0.00%
- Gross Margin
- 77.28%
- Op Margin
- 19.50%
- Net Margin
- 54.34%
- ROE
- 159.72%
- ROIC
- 15.42%
Latest fiscal year · YoY change
- Revenue
- $3.71B+65.2%
- Gross Profit
- $3.04B+57.8%
- Op Income
- $501.58M
- Net Income
- $313.75M+212.8%
- EPS
- $2.39+209.6%
- OCF Growth
- +6405.1%
- FCF Growth
- +1192.7%
- 52W High
- $479.79
- 52W Low
- $143.40
- 50D MA
- $210.88
- 200D MA
- $271.65
- Beta
- 0.27
- RSI (14)
- 26
- Avg Volume
- 2.08M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Alnylam posted 52% year-over-year product revenue growth in Q3, but management said AMVUTTRA demand growth is not yet matching the expanded commercial effort and trimmed full-year TTR expectations to the low end of guidance.· October 29, 2026
- Q3 combined net product revenue rose 52% year over year to about $1.3 billion, led by AMVUTTRA and the TTR franchise.
- TTR product revenue was $1.15 billion, up 59% year over year and 12% sequentially; U.S. TTR revenue grew about $100 million quarter over quarter.
- Management lowered confidence in near-term demand acceleration: the expanded field force is improving physician engagement, but that has not yet translated into faster new patient starts.
- Alnylam expanded TRITON-CM enrollment by 500 patients to 2,250 to improve statistical power for nucresiran, while keeping the expected launch timing around 2030.
- Pipeline progress continued, including encouraging brezosiran Huntington’s data and plans for a pivotal study in 2027 pending regulatory alignment.
Total global net product revenues were approximately $1.3 billion in Q3, up 52% year over year. TTR global net product revenues were $1.15 billion, up 59% year over year and 12% sequentially. U.S. TTR revenue increased by about $100 million quarter over quarter, driven by an $81 million increase in demand, a $17 million inventory benefit, and about $10 million of one-time gross-to-net adjustments. Gross margin on product sales was 72%, down 5% year over year. Non-GAAP R&D expense was $376 million, up 21% year over year, and non-GAAP SG&A was $296 million, up 13% year over year. Non-GAAP operating income was $425 million, down 11% year over year. GAAP net income was $2.2 billion, including a non-cash tax benefit of about $1.9 billion. Cash equivalents and marketable securities ended at $3.6 billion, versus $2.9 billion at year-end 2025. For full-year 2026, management reiterated TTR product sales guidance of $4.2 billion to $4.5 billion but said they now expect to land at the low end of that range. They also said they will not provide 2027 product revenue guidance at JPMorgan and instead will do so with Q4/full-year results in mid-February.
Yvonne Greenstreet said AMVUTTRA’s clinical profile and quarterly dosing position it to be a foundational treatment in ATTR cardiomyopathy, where many patients remain untreated and many physicians are still gaining experience. She emphasized that Alnylam remains confident in the long-term opportunity, but also acknowledged that the company is not yet satisfied with underlying demand growth and needs to convert increased physician engagement into more patient starts. Her tone was confident but candid: the strategy is intact, but execution needs to improve in the near term.
Jeff Poulton focused on the quarter’s financial strength and the mechanics behind reported revenue. He cited $1.3 billion in product revenue, 72% gross margin, $425 million of non-GAAP operating income, and $3.6 billion in cash and marketable securities at quarter-end, while noting that higher AMVUTTRA revenue increased royalty expense to Sanofi and reduced margin by 5% year over year. He also highlighted that Q3 revenue benefited from an $81 million demand increase, a $17 million inventory benefit, and about $10 million of one-time gross-to-net adjustment, but said those items are not underlying demand and that both inventory and price should be headwinds in Q4. On capital allocation, he framed the stronger cash balance as a result of operating performance and continued profitability.
Analysts pressed management on why the expanded sales force is improving engagement but not yet demand; management said newer prescribers often have fewer ATTR-CM patients, more entrenched habits, and need more time and support before converting to starts. On TRITON-CM, Pushkal Garg said the only change was adding 500 patients to improve power as event rates fall with earlier diagnosis and broader background therapy use; he said the study design, endpoint, and launch timing around 2030 remain unchanged. Questions on the proposed 340B CMS rule centered on whether the impact would be pricing or volume; Jeff Poulton said both could move depending on hospital choices, but management does not yet know the final effect and is preparing options such as contracting and alternate sites of care. Analysts also asked whether the 25%+ revenue CAGR through 2030 still holds; Yvonne Greenstreet said the company still believes it has a path to that ambition if it can capture about a third of the U.S. TRX category and keep growing ex-U.S., though she acknowledged near-term demand and payer-policy uncertainty.
The call reinforced that Alnylam’s TTR franchise is still growing quickly, with strong revenue, broad access, and a large untreated patient pool. Management also sounded confident in the long-term opportunity for nucresiran and the broader pipeline, pointing to encouraging Huntington’s data and a planned pivotal path. If execution improves, they believe AMVUTTRA can deepen share over time as more physicians gain experience.
The biggest near-term concern is that the commercial expansion has not yet produced the demand acceleration management expected, and Yvonne explicitly said they do not expect acceleration in Q4 2026. The company also flagged uncertainty from the pending 340B rule and a more restrictive UnitedHealth Medicare Advantage policy, both of which could affect ordering patterns or access. For TRITON-CM, management is mitigating lower event-rate risk by adding patients, which underscores the uncertainty around the trial environment even as confidence in the program remains high.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.7%
- Shares Outstanding
- 133.94M
- Float Shares
- 133.51M
of shares held by institutions
832 13F filers
Buy/sell ratio 1.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ALNY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Cory BookerSenate · NJ | Sell | Aug 11, 26 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | May 12, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jan 29, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jan 11, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Dec 11, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Mar 6, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 10, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jan 31, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Dec 6, 22 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Sep 28, 22 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Nov 13, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Apr 6, 20 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Oct 18, 18 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jun 1, 18 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Capital World Investors | 13.82M | ▲ 2.67M |
| Vanguard Group Inc | 13.55M | ▼ 11.52K |
| Fmr LLC | 12.62M | ▼ 2.40M |
| Blackrock, Inc. | 11.02M | ▲ 112.37K |
| Capital Research Global Investors | 10.94M | ▲ 1.19M |
| T. Rowe Price Investment Management, Inc. | 10.01M | ▲ 4.37M |
| Vanguard Portfolio Management LLC | 6.70M | ▲ 159.53K |
| Vanguard Capital Management LLC | 6.02M | ▼ 11.37K |
| Baillie Gifford & Co | 5.49M | ▲ 3.05M |
| State Street Corp | 3.82M | ▲ 261.62K |
| Invesco Ltd. | 3.74M | ▼ 16.45K |
| Wellington Management Group Llp | 3.48M | ▲ 1.37M |
Held by 1,810 ETFs
Biggest fund positions in ALNY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Greenstreet Yvonne | other | 11,000 |
| Nov 10, 26 | PYOTT DAVID E I | other | 3,780 |
| Nov 10, 26 | PYOTT DAVID E I | other | 3,780 |
| Nov 10, 26 | Sigal Charles Elliott | buy | 1,600 |
| Nov 9, 26 | SCHULMAN AMY W | buy | 1,910 |
| Oct 2, 26 | SUPRAN BRYAN | sell | 1,758 |
| Sep 19, 26 | Greenstreet Yvonne | other | 107 |
| Jun 1, 26 | PYOTT DAVID E I | other | 3,830 |
| Jun 1, 26 | PYOTT DAVID E I | sell | 921 |
| Jun 1, 26 | PYOTT DAVID E I | sell | 1,175 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ALNY coverage
Recent articles, reports, and earnings notes.

Alnylam Pharmaceuticals (ALNY): AMVUTTRA Drives a Buy Case
Alnylam has crossed into profitable commercial-stage biotech, powered by AMVUTTRA and a fast-growing TTR franchise. Valuation is rich, but the company’s revenue growth, cash generation, and pipeline support a Buy rating.

City Therapeutics IPO: What Investors Need to Know
City Therapeutics Inc. (NASDAQ: CTY) is expected to list on October 16, 2026, on the NASDAQ, with the IPO priced at $18.00 per share for 11,111,111 shares. The company has not disclosed a public price range in the calendar data, but the deal was upsized, which points to solid demand. Bull case: early clinical RNAi data and a deep platform story. Bear case: it is still pre-commercial, loss-making, and years away from proving the pipeline.

Should You Buy the TRex Bio IPO? Here's the Setup
TRex Bio Inc. (NASDAQ: TRXB) is expected to list on 2026-10-09, with the IPO priced at $14.00 per share on the NASDAQ. The company offered 8,333,334 shares and disclosed a market cap of $113,287,167 in the calendar data. The bull case is a differentiated immunology platform; the bear case is a clinical-stage biotech with no product revenue and heavy execution risk.
Want a deeper read on ALNY?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Alnylam Pharmaceuticals Expands Sales Force to Accelerate AMVUTTRA Demand
marketbeat.com · Nov 20
Alnylam to Webcast Presentations at Upcoming December Investor Conferences
businesswire.com · Nov 20
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
prnewswire.com · Nov 19
Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years
businesswire.com · Nov 19
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Alnylam Pharmaceuticals, Inc. $ALNY Stake Trimmed by Aberdeen Group plc
defenseworld.net · Nov 18
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
globenewswire.com · Nov 17
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
prnewswire.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice